The National Football League Alumni Association, based in Newark, is working with Neuralstem, Inc. to develop a trial for treating NFL alumni members suffering from traumatic brain injuries, according to a release.
The trial will use NSI-189, the lead compound in Rockville, Md.-based Neuralstem's neurogenic drug platform, which appears to work by stimulating neurons in the hippocampus, a region of the brain that atrophies in depression and which could also be implicated in brain injury.
"The National Football League Alumni Association is focused on this serious health issue, which is destroying quality of life and has tragically led to several high-profile suicides just this past year among our members," said Lee Nystrom, chairman of the board, emeritus, of the NFL Alumni Association, and a former Green Bay Packer, in the release. "We are committed to pursuing both basic research into traumatic brain injury as well as pushing the envelope to create therapies that can improve the quality of life for our members afflicted with these diseases."
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy